Year: 2023
Type: review
Abstract: Breast cancer is the leading cause of cancer in women in Spain and its annual incidence is rapidly increasing. Thanks to the screening programs in place, nearly 90% of breast cancer cases are detected in early and potentially curable stages, despite the COVID-19 pandemic possibly having impacted these numbers (not yet quantified). In recent years, locoregional and systemic therapies are increasingly being directed by new diagnostic tools that have improved the balance between toxicity and clinical benefit. New therapeutic strategies, such as immunotherapy, targeted drugs, and antibody-drug conjugates have also improved outcomes in some patient subgroups. This clinical practice guideline is based on a systematic review of relevant studies and on the consensus of experts from GEICAM, SOLTI, and SEOM.
Institutions: Hospital General Universitario Morales Meseguer, Universidad de Murcia, Complexo Hospitalario Universitario A Coruña, Fundación Instituto Valenciano de Oncología, Hospital Universitario Quirónsalud Madrid, Hospital Universitario Virgen Macarena, Universitat de València, Hospital Clínico Universitario de Valencia, INCLIVA Health Research Institute, Hospital Universitario Reina Sofía, Institut Català d'Oncologia, Hospital Clínic de Barcelona, Hospital Universitario 12 De Octubre, HM Hospitales
Language: English
Subfield: Cancer Research
Domain: Life Sciences
Open Access status: hybrid
Estimated APC paid: $4,290
Funder: Universidad de Murcia
OpenAlex ID: W4380872003